Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF
出版年份 2013 全文链接
标题
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF
作者
关键词
-
出版物
ONCOGENE
Volume 33, Issue 47, Pages 5397-5404
出版商
Springer Nature
发表日期
2013-12-23
DOI
10.1038/onc.2013.544
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Postnatal Expression of BRAFV600EDoes Not Induce Thyroid Cancer in Mouse Models of Thyroid Papillary Carcinoma
- (2013) Mika Shimamura et al. ENDOCRINOLOGY
- Is Thyroid Cancer Recurrence Risk Increased After Transplantation?
- (2013) Hélène Tisset et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways
- (2013) Emad Kandil et al. JOURNAL OF SURGICAL RESEARCH
- Increasing incidence of thyroid cancer: controversies explored
- (2013) Yasuhiro Ito et al. Nature Reviews Endocrinology
- BRAF V600E Inhibition in Anaplastic Thyroid Cancer
- (2013) Michael H. Rosove et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer
- (2013) Steven I. Sherman ORAL ONCOLOGY
- Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600E Mutation
- (2013) Kevin B. Kim et al. THYROID
- Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas
- (2013) Cristina Montero-Conde et al. Cancer Discovery
- Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
- (2012) C. M. Chan et al. CLINICAL CANCER RESEARCH
- New targeted therapies and other advances in the management of anaplastic thyroid cancer
- (2012) Hari A. Deshpande et al. CURRENT OPINION IN ONCOLOGY
- FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma
- (2012) Roberto Bellelli et al. ENDOCRINE-RELATED CANCER
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
- (2012) Robert C. Smallridge et al. THYROID
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Thyroid Cancer: Burden of Illness and Management of Disease
- (2012) Rebecca L. Brown et al. Journal of Cancer
- Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
- (2011) F. Su et al. CANCER RESEARCH
- Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse
- (2011) R.-P. Charles et al. CANCER RESEARCH
- Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model
- (2011) M. K. Gule et al. CLINICAL CANCER RESEARCH
- Late Intervention with anti-BRAFV600ETherapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer
- (2011) Matthew A. Nehs et al. ENDOCRINOLOGY
- Long-Term Follow-Up of Patients with Papillary and Follicular Thyroid Cancer: A Prospective Study on 715 Patients
- (2011) M. Brassard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation
- (2011) Debyani Chakravarty et al. JOURNAL OF CLINICAL INVESTIGATION
- A roadmap for targeted therapies
- (2011) Francesca Carlomagno et al. Nature Reviews Endocrinology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Akt1 deficiency delays tumor progression, vascular invasion and distant metastasis in a murine model of thyroid cancer
- (2011) M Saji et al. ONCOGENE
- Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma
- (2011) C Lu et al. ONCOGENE
- Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
- (2011) C. Nucera et al. ONCOLOGIST
- Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
- (2011) A. T. Franco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Establishment and Genomic Characterization of Mouse Xenografts of Human Primary Prostate Tumors
- (2010) Carmen Priolo et al. AMERICAN JOURNAL OF PATHOLOGY
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
- (2010) Joanna Xing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
- (2010) John Araujo et al. CANCER TREATMENT REVIEWS
- Modeling metastasis in the mouse
- (2010) Paula D Bos et al. CURRENT OPINION IN PHARMACOLOGY
- Akt inhibitors in clinical development for the treatment of cancer
- (2010) Sumanta Kumar Pal et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus
- (2010) Dingxie Liu et al. INTERNATIONAL JOURNAL OF CANCER
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- (2010) E. W. Joseph et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- B-RafV600E and thrombospondin-1 promote thyroid cancer progression
- (2010) C. Nucera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer
- (2010) Matthew A. Nehs et al. SURGERY
- Thyroid Cancer Resistance to Vitamin D Receptor Activation Is Associated with 24-Hydroxylase Levels But Not the ff FokI Polymorphism
- (2010) Vibha Sharma et al. THYROID
- Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
- (2010) Mingzhao Xing THYROID
- Oncogenic Kras Requires Simultaneous PI3K Signaling to Induce ERK Activation and Transform Thyroid Epithelial Cells In vivo
- (2009) K. A. Miller et al. CANCER RESEARCH
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1
- (2009) J. C. Ricarte-Filho et al. CANCER RESEARCH
- Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets
- (2009) Jeffrey A Knauf et al. CURRENT OPINION IN CELL BIOLOGY
- Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience
- (2009) Apostolia Maria Tsimberidou et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Inhibition of Src with AZD0530 Reveals the Src-Focal Adhesion Kinase Complex as a Novel Therapeutic Target in Papillary and Anaplastic Thyroid Cancer
- (2009) Rebecca E. Schweppe et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
- (2009) Motoyasu Saji et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A Novel Orthotopic Mouse Model of Human Anaplastic Thyroid Carcinoma
- (2009) Carmelo Nucera et al. THYROID
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- (2009) David S. Cooper et al. THYROID
- The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis
- (2008) W. Liu et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement
- (2008) Y. C. Henderson et al. CLINICAL CANCER RESEARCH
- Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib
- (2008) Elizabeth Day et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- BRAFV600EMutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines
- (2008) Rebecca Leboeuf et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
- (2008) Rebecca E. Schweppe et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Highly Prevalent Genetic Alterations in Receptor Tyrosine Kinases and Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase Pathways in Anaplastic and Follicular Thyroid Cancers
- (2008) Zhi Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation